Treatment for cancer in Bengal mushrooms? What a researcher’s study says
A researcher from Bengal, Dr. Swapan Kumar Ghosh has discovered a cancer -fighting complex in the Estrius Asiaticus mushroom found in the forests of Bankura and Birbham. His study published in nature’s scientific reports, highlights the compound F12, which shows the ability against cancer of the cervix, breast and lungs.
What can be an important achievement for mankind, the researcher of Bengal, Dr. Swapan Kumar Ghosh has discovered a cancer-killing complex in mushrooms that grow in the forests of Bankura and Birbham. With his team, Dr. Ghosh, who is a professor at Ramakrishna Mission Vivekananda Shatabdi College in Rahera, has tested a product called F12 from Mushroom Estrius Asiaticus, which has the ability to prevent or treat three types of cancer: cervical, breast, and lung cancer.
Talking to India today, Dr. Ghosh told how his upbringing in Khairsol, Birbam brought him to this conclusion. “I was born in Birbum and saw the locals, especially tribals, to eat local mushrooms, and they were resistant to many types of diseases. My student, Kaushik Pandey, who is from Bankura, conducted a survey and found that cancer is less prevalent in the areas of Banura where the locals consume this mushroom. ,
Mushroom, called Estrius Asiaticus Or grows around the surface of trees such as Kurkura mushrooms, mahua or cell, but only during the rainy season.
Dr. Ghosh’s paper, titled “Mycacomry, Antioxidant, Antiquanser Activity, and Ethylus Asiaticus with BCL2 and Caspase 3 were published in the Flew Docking, Nature Scientific Report of Ethylus Asiaticus’s Ethylus Asiaticus’s Ethylus Asiaticus.
“F12 has both antioxidants and anticancer properties. Free radicals, or reactive oxygen species (ROS), are generated during our metabolism and can damage cell membranes, DNA, and other structures, which are probably leading to cancer and other diseases. The antioxidant property of F12 allows it to neutralize and eliminate these harmful free radicals, ”Dr. Ghosh said.
F12 consists of six exclusive compounds that have been beneficial in eliminating human cancer cells during testing. These six compounds are 3,4,5,6-tetramethyloctane, hexadecanoic acid, 9,12-octadecadienoic acid, 9,12-octadecadienoic acid methyl ester, 1-siklododice, and CIS-9,10-10-10-Eclodecodesy. Of these, 3,4,5,6-tetramthyloctene, hexadekanoec acid, and 9,12-octadacadianoic acid demonstrated the anticancer activity, while the 9,12-octadianoinoic acid methyl aster showed an antioxidant activity according to NIST database and library research.
Dr. According to Ghosh, by inducting compounds apoptosis in F12, the cancerous cells display antiquencies, leaking LDH from cells, and upgrade apoptic genes such as Caspase 3 and 9, as well as affect or activate P53 genes. The F12 product prevents anti-apoptotic genes BCL2 to prevent cancer cell division.
Dr. Ghosh further stated that in both cancer and normal cells, CYP1A and CYP2C9 proteins are present. These proteins reject anticancer drugs from cancer cells, which contribute to drug resistance to patients. However, the F12 has a tendency to bind with two compounds, hexadacian acids and 9,12-octadacedianoic acids, CYP1A and CYP2C9, preventing them. As a result, six compounds in F12 are not expelled or rejected by cancer or normal cells, making F12 resistant to drug rejection.
“What is more important is that the F12 compound does not have a negative effect on the body. This does not harm any other cells. Chemotherapy kills cancer cells, but also affects healthy cells, affects the body, ”Dr. Ghosh said.
So, what’s next? Dr. Ghosh is preparing for human testing and planning to cooperate with a government hospital in the city.
“I am confident that we will pass human tests, as this compound has the ability to develop in a drug. We hope this compound can help cure cancer,” Dr. Ghosh said.
